Evaluating a new algorithm for diagnosing ADHD in youth aged 6 to 17.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the accuracy of the MT1 algorithm, which utilizes the MindTension biometric sensor device, as a diagnostic aid for ADHD in children and adolescents aged 6 to 17. The MT1 algorithm's output will be compared to a gold standard clinical diagnosis made by specialists using the Kiddie SADS Present and Lifetime semi-structured interview and the ADHD-RS-5 rating scale. The study will also evaluate whether the agreement between the MT1 output and specialist diagnoses is non-inferior to that of the TOVA Continuous Performance Test. Participants will include both diagnosed ADHD patients and a control group without ADHD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Parent provision of signed and dated informed consent form
2. Child stated willingness to comply with all study procedures and availability for the duration of the study
3. Any gender, aged 6 to 17 years
4. Stimulant naïve or willing to wash out of stimulant for 3 days (approximately 72 hours) prior to testing with biometric and performance devices (MindTension + TOVA)
5. ADHD Group: Diagnosed with symptoms consistent with ADHD as determined by Mini Kid + an ADHD-RS score of 1.5SD above mean for age and sex
6. Control group: No diagnosable disorder on the Mini kid, and an ADHD-RS score within 1SD of the mean for age and sex.

Exclusion Criteria:

1. Current use of psychotropic medications that cannot be washed out in 3 days (approximately 72 hours)
2. Known current seizure disorder (history of febrile seizure allowed).
3. Presence of specific devices (e.g., cardiac pacemaker) that may interfere with the MindTension monitor
4. IQ\<70 by clinician judgment
5. Meeting FULL criteria for current PTSD, GAD, MDD, or any lifetime diagnosis of ASD, Bipolar disorder, or psychotic disorder that was, in the opinion of the investigator, correctly obtained. May have symptoms of anxiety or dysthymia/depression not meeting criteria for a full disorder, or disorders such as simple phobia
6. Deaf or hearing impaired, since this will make it difficult to hear and respond to the auditory stimuli.
7. Inability to complete the assessments.
8. Any other concerns in the judgment of the PI.

Where it's running

• Icahn School of Medicine at Mount Sinai
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Jeffrey Newcorn, MD Professor — Director, Division of ADHD and Learning Disorders Icahn School of Medicine at Mount Sinai
• Study coordinator: Jeffrey Newcorn, MD Professor
• Email: jeffrey.newcorn@mssm.edu
• Phone: 212-659-8705

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Biomarkers that predict medication-related side effects in children with ADHD

  This study tests whether combined brain, cognitive, and metabolite markers can predict side effects from methylphenidate in kids with ADHD.

  Recruiting National Taiwan University Hospital · Taipei, Taiwan · NCT07900451

• Group CBT vs. Activity Group for Adults with ADHD

  This trial tests whether group cognitive behavioral therapy helps adults with ADHD more than a structured activity group.

  Recruiting at 2 sites Region Stockholm · Stockholm and 1 other locations · NCT07834437

• Central Executive Training and Behavioral Parent Training for Young Children with ADHD

  This study tests Central Executive Training (CET) alone and CET combined with Behavioral Parent Training (BPT) to help young children with ADHD.

  Recruiting Florida State University · Tallahassee, Florida · NCT07784348

• Solriamfetol for ADHD in teens: see if it helps with focus

  This phase 3 study tests solriamfetol versus placebo in adolescents with ADHD to see if the medication improves symptoms over 6 weeks.

  Recruiting at 31 sites Phase 3 Axsome Therapeutics, Inc. · Dothan, Alabama and 30 other locations · NCT07717892

• Solriamfetol for children with ADHD: a 6-week comparison to placebo

  This trial tests whether solriamfetol can help children aged 6 to under 12 with ADHD, compared to placebo, over six weeks.

  Recruiting at 32 sites Phase 3 Axsome Therapeutics, Inc. · Dothan, Alabama and 31 other locations · NCT07717879

• Impact of Sleep Timing and Duration on Teens with ADHD

  This study tests how changing how long and when teens with ADHD sleep affects their attention and daily functioning.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07684417

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.